ReviewJournal of immunology (Baltimore, Md. : 1950)2026
CD8+ lymphocytes in immunity against tuberculosis.
Review in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Tuberculosis (TB) is a major global health threat. Deep knowledge of the immune responses against Mycobacterium tuberculosis (Mtb) is crucial for developing effective interventions. Data support that both innate and adaptive CD8+ lymphocytes contribute to protective immunity in Mtb infections, commonly attributed to the expression of cytotoxic effectors. They can also produce proinflammatory cytokines that activate macrophages to enhance antimycobacterial responses. However, the roles and functions of the various CD8+ lymphocyte subsets in TB protection and pathogenesis are complex, as excessive activation can lead to tissue damage and exacerbate disease severity, while CD8+ lymphocytes with anti-inflammatory functions may limit inflammation and damage. Understanding the heterogeneity of CD8+ lymphocyte responses and dynamics in TB can provide critical insights for designing efficacious vaccines and immunotherapies while minimizing immunopathology. This review focuses on the current understanding of roles for different CD8+ lymphocyte subsets in responses against Mtb and implications for novel vaccine and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.